Attempts to discern how mutations in the LRRK2 gene contribute to Parkinson’s disease have focused largely on the protein’s role as a kinase. In the January 8 Journal of Neuroscience, researchers led ...

The LRRK2 variant is strongly associated with symptoms of Parkinson’s disease (PD) that are different from non-variant carriers with the disease The study revealed novel findings of genetic “hotspots” ...

For the first time, researchers have solved the molecular structure of LRRK2, a major risk factor for Parkinson’s and autoimmune diseases. Structural biologists at the University of California, San ...

Future Neurology. 2012;7(2):145-153. Taken together, the present studies do not support a direct biochemical interaction between α-syn and LRRK2, or direct phosphorylation of α-syn by LRRK2, which ...

Parkinson's disease-related protein LRRK2 structure solved using a trailblazing new technique, revealing its surprising organization in cells, and paving the way for a treatment SAN DIEGO, CA - The ...

The role played by mutations in the LRRK2 gene in promoting Parkinson's disease has long intrigued scientists, and even led to an experimental drug that inhibits the over-active protein. Yet exactly ...

The impairment of midbrain nigrostriatal dopaminergic innervation at the striatum and the resulting imbalance of striatal output via the direct and indirect pathways underlie the neurological basis of ...

Neuron23® Inc., a clinical-stage biotechnology company on a mission to transform the future of Parkinson’s disease through precision medicine, today announced it has received a $2.5 million grant from ...

For the roughly one million Americans living with Parkinson’s disease, every approved treatment does the same thing: manage symptoms. None slows the underlying brain degeneration. Results published in ...

See more of our trusted coverage when you search. Prefer Newsweek on Google to see more of our trusted coverage when you search. A new treatment for one type of Parkinson's disease may be on the ...

The role played by mutations in the LRRK2 gene in promoting Parkinson’s disease has long intrigued scientists, and even led to an experimental drug that inhibits the over-active protein. Yet exactly ...